T. Rowe Price Associates, Inc. 13D and 13G filings for Karuna Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 10:03 am Sale | 2023-12-31 | 13G | Karuna Therapeutics, Inc. KRTX | T. Rowe Price Associates, Inc. | 1,963,957 5.200% | -399,347 (-16.90%) | Filing |
| 2023-02-14 12:38 pm Purchase | 2022-12-31 | 13G | Karuna Therapeutics, Inc. KRTX | T. Rowe Price Associates, Inc. | 2,363,304 6.900% | 407,938 (+20.86%) | Filing |
| 2022-02-14 2:34 pm Purchase | 2021-12-31 | 13G | Karuna Therapeutics, Inc. KRTX | T. Rowe Price Associates, Inc. | 1,955,366 6.600% | 531,205 (+37.30%) | Filing |